The Analyst Verdict: Health Catalyst In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have shared their insights on Health Catalyst (NASDAQ:HCAT), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 5.08% to $11.2. Analysts have recently adjusted their ratings and price targets, reflecting a negative shift in sentiment.
August 09, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have mixed views on Health Catalyst (NASDAQ:HCAT) with a recent decrease in the average 12-month price target by 5.08% to $11.2. Recent ratings adjustments reflect a negative shift in sentiment.
The decrease in the average price target and the lowering of ratings by multiple analysts indicate a negative shift in sentiment towards Health Catalyst. This could lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100